Neurocrine Biosciences (NASDAQ:NBIX) Given Outperform Rating at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research note published on Wednesday, Benzinga reports. Oppenheimer currently has a $200.00 price target on the stock.

A number of other equities analysts have also weighed in on NBIX. Needham & Company LLC reiterated a hold rating on shares of Neurocrine Biosciences in a research report on Tuesday. Mizuho increased their price target on Neurocrine Biosciences from $116.00 to $140.00 and gave the company a neutral rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $148.00 to $158.00 and gave the company an overweight rating in a research report on Wednesday, March 20th. The Goldman Sachs Group raised their price objective on Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a buy rating in a research report on Thursday, January 25th. Finally, Citigroup decreased their price objective on Neurocrine Biosciences from $141.00 to $140.00 and set a neutral rating for the company in a research report on Thursday, February 8th. Six research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $142.38.

Neurocrine Biosciences Trading Down 0.8 %

Neurocrine Biosciences stock opened at $138.97 on Wednesday. The stock has a market cap of $13.83 billion, a P/E ratio of 57.43 and a beta of 0.25. Neurocrine Biosciences has a 52 week low of $89.04 and a 52 week high of $148.37. The stock has a 50 day moving average of $136.48 and a 200-day moving average of $127.62.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The company had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The company’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same period last year, the company earned $0.88 earnings per share. As a group, equities analysts predict that Neurocrine Biosciences will post 4.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total value of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares in the company, valued at approximately $3,909,454.64. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Neurocrine Biosciences news, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the transaction, the director now directly owns 29,512 shares in the company, valued at approximately $3,909,454.64. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Matt Abernethy sold 1,352 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $132.85, for a total value of $179,613.20. Following the transaction, the chief financial officer now owns 31,528 shares in the company, valued at $4,188,494.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 186,994 shares of company stock valued at $25,806,409. 4.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Large investors have recently added to or reduced their stakes in the company. FCF Advisors LLC bought a new position in Neurocrine Biosciences in the 4th quarter worth about $1,157,000. Redhawk Wealth Advisors Inc. bought a new position in Neurocrine Biosciences in the 4th quarter worth about $1,245,000. HealthInvest Partners AB bought a new position in Neurocrine Biosciences in the 4th quarter worth about $1,662,000. Roman Butler Fullerton & Co. bought a new position in Neurocrine Biosciences in the 4th quarter worth about $1,256,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Neurocrine Biosciences by 128.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,939 shares of the company’s stock worth $5,921,000 after purchasing an additional 25,245 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.